Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10254340 | 0.83 | RAB9A (0.45) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL1276487 | 0.81 | RAB9A (0.46) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL21783617 | 0.81 | TAAR1 (0.47) | RAB9ANPC1 | |
| SCHEMBL11927944 | 0.79 | RAB9A (0.42) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL14015076 | 0.79 | RAB9A (0.44) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL292900 | 0.78 | RAB9A (0.45) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL1317917 | 0.78 | RAB9A (0.45) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL2035570 | 0.78 | PRKCI (0.49) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL2773998 | 0.78 | TAAR1 (0.56) | RAB9AKDM1AMAOAMAOBNPC1 | |
| SCHEMBL29997560 | 0.78 | RAB9A (0.45) | RAB9AKDM1AMAOAMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312455-A1 | Method For Determining Enantiomeric Purity Of Darifenacin And Intermediates | MEDICHEM, S.A. (ES) | 2008-12-18 | — | — | US | disclosed |
| US-20080312455-A1 | Method For Determining Enantiomeric Purity Of Darifenacin And Intermediates | MEDICHEM, S.A. (ES) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312455-A1 | Method For Determining Enantiomeric Purity Of Darifenacin And Intermediates | OPRL1, ADRB3, ADRB1 | RAB9A 2725/4885KDM1A 3269/4885MAOA 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.